Skip to main content
Premium Trial:

Request an Annual Quote

EU Awards $3.9M to European Colon and Breast Cancer Biomarker Consortium

NEW YORK (GenomeWeb News) — A pan-European project created to discover biomarkers for monitoring and following patients with breast and colon cancer has received a €2.9 million ($3.9 million) grant from the European Union, project partner Ipsogen said today. 
The nine-member project, called Colon and Breast Cancer Diagnostics, or COBRED, is being coordinated by Paris-based Biosystems International, and the funding is being administered under the EU’s Sixth Framework Program.
Ipsogen said that COBRED after three years aims to deliver a set of biomarker candidates that have been verified in preclinical studies and will be ready for large-scale clinical validation, development, and commercialization by the three corporate biotech partners.
In addition to Biosystems International and Ipsogen, the Austrian metabolomics company Biocrates is involved in the project.
The consortium has three academic partners, including Austria’s University of Innsbruck, Estonia’s University of Tartu, and Hungary’s University of Debrecen.
COBRED also will use resources such as bio-samples from two French cancer centers, including Paris’ Curie Institute and the Gustave Roussy Institute in Villejuif.
Ipsogen said that although COBRED is focused on biomarkers for follow-up diagnostics, the research could potentially develop an early cancer-detection and screening tool.
Ipsogen CEO Vincent Fert called the project “a powerful research platform” for “aggregating major technologies and clinical expertise” that will develop tools for monitoring breast and colon cancers.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.